333 related articles for article (PubMed ID: 28334439)
81. Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma.
Pala L; Conforti F; Cocorocchio E; Ferrucci PF
Anticancer Drugs; 2020 Jul; 31(6):652-654. PubMed ID: 32011367
[TBL] [Abstract][Full Text] [Related]
82. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
[TBL] [Abstract][Full Text] [Related]
83. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
84. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
85. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Algazi AP; Weber JS; Andrews SC; Urbas P; Munster PN; DeConti RC; Hwang J; Sondak VK; Messina JL; McCalmont T; Daud AI
Br J Cancer; 2012 Jan; 106(1):85-91. PubMed ID: 22127285
[TBL] [Abstract][Full Text] [Related]
86. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
87. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
88. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.
Schuetze SM; Wathen JK; Lucas DR; Choy E; Samuels BL; Staddon AP; Ganjoo KN; von Mehren M; Chow WA; Loeb DM; Tawbi HA; Rushing DA; Patel SR; Thomas DG; Chugh R; Reinke DK; Baker LH
Cancer; 2016 Mar; 122(6):868-74. PubMed ID: 26710211
[TBL] [Abstract][Full Text] [Related]
89. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
90. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
91. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
92. Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y; Si L; Zhu Y; Xu X; Corless CL; Flaherty KT; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lu A; Guo J
Clin Cancer Res; 2011 Apr; 17(7):1684-91. PubMed ID: 21325067
[TBL] [Abstract][Full Text] [Related]
93. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
[TBL] [Abstract][Full Text] [Related]
94. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
Bai X; Mao LL; Chi ZH; Sheng XN; Cui CL; Kong Y; Dai J; Wang X; Li SM; Tang BX; Lian B; Zhou L; Yan XQ; Guo J; Si L
Neoplasma; 2017; 64(4):626-632. PubMed ID: 28485171
[TBL] [Abstract][Full Text] [Related]
95. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Daud A; Kluger HM; Kurzrock R; Schimmoller F; Weitzman AL; Samuel TA; Moussa AH; Gordon MS; Shapiro GI
Br J Cancer; 2017 Feb; 116(4):432-440. PubMed ID: 28103611
[TBL] [Abstract][Full Text] [Related]
96. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
97. Management of vulvar and vaginal melanomas: current and future strategies.
Leitao MM
Am Soc Clin Oncol Educ Book; 2014; ():e277-81. PubMed ID: 24857113
[TBL] [Abstract][Full Text] [Related]
98. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Cho J; Kim SY; Kim YJ; Sim MH; Kim ST; Kim NKD; Kim K; Park W; Kim JH; Jang KT; Lee J
Clin Transl Oncol; 2017 Oct; 19(10):1247-1252. PubMed ID: 28421416
[TBL] [Abstract][Full Text] [Related]
99. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
[TBL] [Abstract][Full Text] [Related]
100. Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.
Tang B; Duan R; Zhang X; Qin S; Wu D; Chen J; Yao H; Chi Z; Guo J; Yan X
Oncologist; 2024 Jun; 29(6):e822-e827. PubMed ID: 38547052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]